Literature DB >> 27810230

Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.

F Magne1, S Durupt1, R Nove-Josserand1, F Bey-Omar2, L Laoust3, V Cottin4, I Durieu1, Q Reynaud5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27810230     DOI： 10.1016/j.jcf.2016.10.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN： 1569-1993            Impact factor:   5.482


× No keyword cloud information.
  1 in total

Review 1.  Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.

Authors:  Misak Harutyunyan; Yunjie Huang; Kyu-Shik Mun; Fanmuyi Yang; Kavisha Arora; Anjaparavanda P Naren
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-12-14       Impact factor: 5.464
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.